Human LR3 insulin-like Growth Factor-I (LR3IGF-I) is an 83 amino acid analogue of IGF-I comprising the complete human IGF-I sequence with the substitution of an Arginine for the Glutamine at position 3,plus a 13 amino acid extension peptide at the N-terminus.

Human LR3IGF-I is more potent than IGF-I in vitro and in vivo. This increased potency is due to reduced binding of LR3IGF-I to most of the IGF binding proteins which modify the biological actions of IGF-I.

Human LR3IGF-I binds to the type 1 IGF receptor with similar affinity to wild type IGF-I.LR3

IGF-I was developed by GroPep specifically for supplementation of mammalian cell culture to support the survival and proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II and has several advantages over recombinant insulin. Supplementation of cell cultures with LR3IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3IGF-I is better able to stimulate the type I IGF receptor and thus induce a higher level of activation of intracellular signalling molecules which are responsible for promoting cell survival by inhibition of apoptosis.

Media grade LR3IGF-I is a high quality product for use in commercial cell culture.It can also be used as a research reagent at an economical cost to enable studies where higher quantities of peptide are required.

References Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223

Yandell C et al (2004) Bioprocess International 2, 56-64

Source: Produced in E.coli.

Molecular Weight: 9110.6 ± 2 Daltons

Purity: ≥ 95 % (by SDS gel electrophoresis)

HPLC analysis: Three peaks with main peak being > 50% of total area

(Other species are micro heterogeneous forms which have biological activity)

N-terminal sequence: Analysis of 18 residues

Biological Activity: Proliferation of Chinese Hamster Ovary (CHO) cells

(EC50 ≤ 10 ng/ml)

Endotoxin: ≤ 0.1 EU/µg

Appearance: White powder freeze-dried from 0.1M acetic acid and stored under

nitrogen at a slight vacuum.

Storage/Stability: At least 2 years at 2-8°C (as a freeze dried product).

Reconstitution: Handling of GroPep IGF-I, IGF-II and IGF analogues

艾美捷LR3胰島素樣生長因子-I#GRO-AM001是IGF-I的83個氨基酸的類似物，其包含在位置3用精-氨-酸取代谷-氨-酰-胺的完整人IGF-I序列，加上在N-末端的13個氨基酸的延伸肽。

人類LR3 IGF-I在體外和體內都比IGF-I更有效。這種效力的提高是由于LR3的結合IGF-I與大多數(shù)改變IGF-I生物作用的IGF結合蛋白結合。

人類LR3 IGF-I以與野生型IGF-I相似的親和力與1型IGF受體結合。LR3型IGF-I由GroPep開發(fā)，專門用于補充哺乳動物細胞培養(yǎng)物支持細胞的存活和增殖。它被設計成具有比天然IGF-I或IGF-II，并且與重組胰島素相比具有幾個優(yōu)點。細胞的補充含有LR3的培養(yǎng)物IGF-I在低得多的濃度下產生與補充標準濃度的胰島素。LR3型IGF-I能夠更好地刺激I IGF受體，從而誘導更高水平的細胞內信號分子激活負責通過抑制細胞凋亡來促進細胞存活。

LR3胰島素樣生長因子-I詳細信息：

來源：產自大腸桿菌。

分子量：9110.6±2道爾頓

純度：≥95%（SDS凝膠電泳）

HPLC分析：三個峰，主峰面積大于總面積的50%

（其他物種是具有生物活性的微異質形式）

N端序列：18個殘基的分析

生物活性：中國倉鼠卵巢（CHO）細胞的增殖

（EC50≤10 ng/ml）

內毒素：≤0.1 EU/µg

外觀：從0.1M乙酸中冷凍干燥的白色粉末，在

在輕微真空下的氮氣。

儲存/穩(wěn)定性：在2-8°C下至少保存2年（作為冷凍干燥產品）。

重組：GroPep IGF-I、IGF-II和IGF類似物的處理

LR3胰島素樣生長因子-I相關研究：

人LR3IGF-I（受體級）

人[Arg3]IGF-I（介質級）

人LR3IGF-I ELISA

人IGF-I（介質級）

文獻參考：

Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223 Yandell C et al (2004) Bioprocess International 2, 56-64